Fox Run Management’s Immuneering IMRX Stock Holding History

Fox Run Management’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-51,773	Closed	-$341K	–	1050
2025 Q4	$341K	Buy	+51,773	New	+$332K	0.05%	651

Other funds holding IMRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OCM

Occam Crest Management Darien, Connecticut $165M AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fox Run Management's IMRX Position: Q1 2026 in Review

Fox Run Management sold out of Immuneering (IMRX) in Q1 2026, closing a stake of 51,773 shares — an estimated $341K sold.

Fox Run Management first reported a position in IMRX in Q4 2025 and held it in 1 quarter. The position peaked at $341K in Q4 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

Fox Run Management reported no remaining Immuneering position as of Q1 2026 after selling out during the quarter.
Fox Run Management sold 51,773 Immuneering shares in Q1 2026, an estimated $341K.
Fox Run Management first reported a position in Immuneering in Q4 2025 and held it in 1 quarter.
Fox Run Management's Immuneering position peaked at $341K in Q4 2025.
95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.